rs17309872 — GSS

GSS rs17309872 — When the Final Step of Glutathione Synthesis Falls Short

Glutathione (GSH) is often called the body's master antioxidant — and for good reason. This small tripeptide neutralizes reactive oxygen species, conjugates toxins for excretion, recycles vitamins C and E, and drives Phase II detoxification in the liver. The enzyme glutathione synthetase (GSS¹¹ GSS
EC 6.3.2.3, catalyzes the final ATP-dependent step of glutathione biosynthesis) carries out the second and final step of glutathione synthesis, linking gamma-glutamylcysteine with glycine to form the complete GSH tripeptide. The rs17309872 variant lies approximately 500 bp downstream of the GSS gene on chromosome 20 and appears to tag a haplotype associated with reduced glutathione synthesis capacity — evidenced by its association with poorer outcomes in populations under high oxidative stress.

The Mechanism

The GSS gene sits on the minus strand of chromosome 20q11.22. The rs17309872 A→T substitution (plus-strand notation) falls in the 3' downstream region, where it likely influences regulatory elements²² regulatory elements
3'-flanking regulatory sequences can affect transcript stability, polyadenylation efficiency, and expression level of the upstream gene that modulate GSS expression or mRNA stability. It was identified as a tagSNP³³ tagSNP
A tagging SNP captures genetic variation across a haplotype block through linkage disequilibrium (r²≥0.8), serving as a proxy for nearby functional variants in a systematic glutathione pathway survey, meaning it tags a broader haplotype that likely includes functional variants affecting GSS activity. The consequence: carriers of the T allele show an association with reduced glutathione synthesis capacity, particularly under conditions of high oxidative demand — such as platinum-based chemotherapy.

The Evidence

The primary evidence for rs17309872 comes from a large prospective cohort study by Li et al. 2011⁴⁴ Li et al. 2011
Li Y et al. Genetic variations in multiple drug action pathways and survival in advanced-stage non-small cell lung cancer treated with chemotherapy. Clin Cancer Res. 2011 examining 1,076 advanced-stage NSCLC patients. Among 894 tagSNPs in 70 pathway genes, rs17309872 in GSS emerged as the most significant variant in the glutathione metabolism pathway, associated with a hazard ratio of 1.45 (95% CI 1.20–1.70, p=1.47E-04) for poorer overall survival in carriers of the T allele under a dominant model. Median survival was 1.80 years for AA homozygotes vs 1.46 years for AT/TT carriers. The overall gene-level signal for GSS was also significant (p=3.76×10⁻²). The biological interpretation is straightforward: platinum-based chemotherapy generates substantial reactive oxygen species; patients with lower glutathione synthesis capacity have less GSH available to neutralize this oxidative burden and to conjugate platinum compounds for excretion.

Supporting evidence comes from a study of related GSS variants⁵⁵ related GSS variants
Ke HL et al. Genetic variations in glutathione pathway genes predict cancer recurrence in patients treated with transurethral resection and BCG instillation for non-muscle invasive bladder cancer. Ann Surg Oncol. 2015 showing that multiple GSS SNPs (rs7265992, rs6060124, rs7260770, rs4911455) predict cancer recurrence in bladder cancer patients. The cumulative burden of unfavorable GSS genotypes conferred a 6.2-fold higher recurrence hazard — demonstrating that GSS haplotype structure broadly influences clinical outcomes in oxidative stress-sensitive conditions.

Practical Actions

The most direct response to reduced GSS activity is ensuring ample substrate supply. GSS combines gamma-glutamylcysteine with glycine in the final step; both glycine and cysteine availability limit how much glutathione the enzyme can produce. The combination of glycine and N-acetylcysteine (GlyNAC) has shown clinical promise: a 16-week randomized controlled trial by Kumar et al. 2022⁶⁶ Kumar et al. 2022
Kumar P et al. Supplementing GlyNAC in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, and aging hallmarks. J Gerontol A Biol Sci Med Sci. 2022 restored muscle glutathione by 164% and reduced plasma oxidative stress markers (TBARS, F2-isoprostanes) by approximately 72%. Monitoring erythrocyte glutathione levels provides a practical way to assess individual glutathione status and guide supplementation decisions.

Interactions

rs17309872 operates in the same glutathione biosynthesis pathway as upstream variants including GCLC (glutamate-cysteine ligase, the rate-limiting enzyme) and GCLM (the modulatory subunit). Individuals with reduced activity at both the upstream and downstream steps of glutathione synthesis would face compounded GSH depletion. The GST genes (GSTM1, GSTT1, GSTP1) that use glutathione as a cofactor for Phase II detoxification would also be functionally compromised if GSH availability is reduced. Related GSS SNPs (rs7265992, rs6060124) are in linkage disequilibrium with rs17309872 and likely tag the same functional haplotype.